We are focused on the discovery, development and
commercialization of first-in-class treatments for
Leveraging the body’s
VBL’s clinical pipeline is based on two platform technologies that enhance natural physiologic and genetic regulatory elements.
Our product candidates
Our lead candidate is VB-111, a gene-based biologic agent for solid tumor indications which we have advanced to programs for recurrent glioblastoma, ovarian cancer and thyroid cancer.